MetaCap

Zevra Therapeutics Inc. (ZVRA)

NASDAQ: ZVRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

8.76-0.31 (-3.42%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ZVRA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$521.26M
52-week range
8.01 – 15.04
Day range
8.70 – 9.20
Volume / Avg
1.15M / 954.53K
Beta
—

52-week range

$8.01$15.04

ZVRA stock today

Shares of Zevra Therapeutics (ZVRA) finished lower on Nov 20 at $8.76, a drop of 3.42% or $0.31 per share, versus the S&P 500's 3.70% decline. Shares are 41.7% below their 52-week high of $15.04, set on Jul 8, 2026 and 9.4% above the 52-week low of $8.01, near the bottom of the past year's range. ZVRA is down 2.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 1.9%.

Zevra Therapeutics trades at 7.2x its trailing twelve-month earnings per share of $1.22. Its forward P/E of 9.8x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Zevra Therapeutics

Company profile

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Neil F. McFarlane
Headquarters
Boston, MA
Employees
61
Website
zevra.com

Financial highlights

Full financials

In fiscal 2025, Zevra Therapeutics generated $106.5 million in revenue, up 350.9% from fiscal 2024. Net income was $83.2 million, for a net margin of 78.2% versus a median of -167.7% in the prior 5 years. Gross margin was 84.5% (up from 68.6%) and operating margin -59.1%.

Zevra Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$106.47M$23.61M$27.46M$10.16M$28.65M
Growth+350.91%-14.02%+170.26%-64.53%+115.61%
Net income$83.23M$-105.51M$-46.05M$-26.77M$-8.55M
EPS (diluted)$1.35$-2.28——$-2.11

Analyst forecast

Forecast

Consensus (9 analysts)

strong_buy

Avg. price target

$23.00+162.56%

  • Strong buy 2
  • Buy 7
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $18.00High $35.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 3, 2026
EPS actual vs est.
$0.26 vs $0.14
Surprise
+85.71%

ZVRA news

All ZVRA news

Zevra Therapeutics peers

Health Care sector
ZVRA peer companies
CompanyPrice% ChgMarket capCompare
ALMSAlumis Inc.3.96-8.54%$514.09Mvs ZVRA
WVEWave Life Sciences Inc.2.56-5.88%$504.91Mvs ZVRA
CLYMClimb Bio Inc.9.19-0.97%$539.80Mvs ZVRA
CBIOCrescent Biopharma Inc.13.00+0.70%$543.21Mvs ZVRA
AVBPArriVent BioPharma Inc.10.52-6.57%$544.13Mvs ZVRA
ACRSAclaris Therapeutics Inc.3.44-1.71%$545.63Mvs ZVRA
ANLAdlai Nortye Group Ltd. ADR8.55-5.63%$550.60Mvs ZVRA
HELPHelus Pharma Inc.6.11-9.88%$487.68Mvs ZVRA

Indexes, lists and sector

Zevra Therapeutics stock FAQ

What is Zevra Therapeutics's stock price today?

ZVRA last traded at $8.76 as of Nov 20, 4:00 PM EST, down 3.42% on the day. Prices are delayed at least 15 minutes.

Does Zevra Therapeutics pay a dividend?

No. Zevra Therapeutics does not currently pay a regular cash dividend.

What is ZVRA's P/E ratio?

ZVRA trades at a trailing P/E ratio of 7.18 and a forward P/E of 9.84.

Who is Zevra Therapeutics's CEO?

Mr. Neil F. McFarlane is the chief executive officer of Zevra Therapeutics Inc., which has about 61 employees.

Has ZVRA ever split its stock?

Yes. The most recent ZVRA stock split was a 1-for-16 split on Dec 28, 2020.

What is the ZVRA 52-week high?

The 52-week high for ZVRA is $15.04 and the 52-week low is $8.01. The stock is currently 41.7% below its high.

Compare ZVRA